Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer

NCT04409002 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04409002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 23, 2020
Completion date
February 25, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, pancreatic cancer